Every 424B that Q32 Bio Inc. (QTTB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow QTTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTTB filings page.
Q32 Bio Inc. is registering the resale of up to 6,875,000 shares of common stock by existing investors under a shelf prospectus. This includes 6,725,000 shares already outstanding and 150,000 shares issuable upon exercise of pre-funded warrants issued in a May 26, 2026 private placement.
The company is not selling shares in this offering and will receive no proceeds from resale, though it may receive nominal cash if pre-funded warrants are exercised. Q32 Bio is a clinical-stage biotech focused on bempikibart for alopecia areata and related autoimmune conditions. It previously restructured to prioritize bempikibart and sold ADX-097 rights to Akebia Therapeutics. The stock trades on Nasdaq as “QTTB” and closed at $15.21 on July 27, 2026, with 29,763,999 shares outstanding as of July 16, 2026.
Q32 Bio Inc. is conducting a primary offering of 6,027,399 shares of common stock and pre-funded warrants to purchase up to 4,931,506 shares at $18.25 per share (or $18.2499 per warrant), for total public offering proceeds of $199,999,523.0994 and estimated net proceeds of about $187.59 million.
Shares outstanding will be 29,708,814 after the transaction, or 31,352,649 if the underwriters’ option for 1,643,835 additional shares is exercised in full, excluding any warrant exercises; this is a baseline figure, not the amount being offered. New investors incur immediate dilution of about $8.13 per share relative to the as adjusted net tangible book value of $10.12.
The company plans to use the cash, together with existing funds, for working capital, including research, clinical development and commercialization, particularly advancing its alopecia areata candidate bempikibart into future trials. Q32 Bio highlights favorable 36‑week safety and pharmacokinetic data from the SIGNAL‑AA Part B study and notes repayment of approximately $6.8 million to terminate its loan with Silicon Valley Bank, while emphasizing that its stock and the non‑listed pre‑funded warrants can be volatile and illiquid and that investing involves significant risks.
Q32 Bio Inc. is conducting a primary offering of up to $200,000,000 of common stock and pre-funded warrants under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $30,000,000 of common stock. The transaction also covers shares issuable upon exercise of the pre-funded warrants, which are exercisable immediately at $0.0001 per share, subject to ownership caps, and are not expected to trade on an exchange.
The company is a clinical-stage biotechnology firm focused on bempikibart (ADX-914) for alopecia areata and other autoimmune diseases. Part B of the Phase 2a SIGNAL-AA trial in 33 severe patients used a 36-week subcutaneous dosing regimen and showed a generally well-tolerated safety profile without treatment-related serious adverse events, while an open-label extension from Part A indicated durable hair growth supporting maintenance dosing. Management plans to advance bempikibart into a registration-directed program in the first half of 2027.
Q32 Bio previously reoriented its strategy around bempikibart, including a 2025 asset sale of ADX-097 to Akebia Therapeutics while retaining earlier-stage complement assets. As of March 31, 2026, net tangible book value was $46.3 million, or $3.17 per share, with 14,629,463 shares outstanding before subsequent PIPE and at-the-market issuances. On June 24, 2026, the company repaid approximately $6.8 million, terminating its loan with Silicon Valley Bank.
Q32 Bio Inc. is registering $75,000,000 of common stock for sale from time to time through or to Cantor Fitzgerald & Co. under a Controlled Equity Sales Agreement as an at-the-market offering. The sales agent may act as agent or principal and is entitled to a 3.0% commission on gross proceeds. The company previously sold $14,200,000 under the prior prospectus supplement and has terminated that prior supplement. The number of shares outstanding was 12,858,047 as of December 31, 2025, and the prospectus assumes an illustrative price of $6.48 per share.
Net proceeds will be received by the issuer and are planned for working capital and clinical development, including support of bempikibart (ADX-914) development in alopecia areata. Sales may occur at varying prices and times; Cantor has no obligation to sell any set amount and the offering may be suspended or terminated per the sales agreement.
Q32 Bio Inc. is offering up to $14,200,000 of Common Stock through an at-the-market sales agreement with Cantor Fitzgerald & Co.
The company may sell shares from time to time under the sales agreement, with Cantor acting as sales agent or principal and receiving a 3.0% commission on gross proceeds. Sales are intended to be conducted as an at the market offering and are subject to the terms of the sales agreement. The prospectus supplement cites a March 26, 2026 last reported sale price of $7.14 per share and discloses a public float calculation used to limit offerings under Form S-3 General Instruction I.B.6.
Q32 Bio is offering 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares, raising approximately $10.5 million before expenses at $3.90 per share. The pre-funded warrants are priced at $3.8999 and carry a nominal exercise price of $0.0001 per share.
Net proceeds of about $10.3 million will fund working capital, research and clinical development, particularly advancing lead antibody bempikibart for alopecia areata and future trials. The company highlights that investors will experience immediate and substantial dilution, and future equity financings could further dilute existing holders.
Pre-funded warrants are immediately exercisable, do not trade on any exchange and have beneficial ownership limits, generally capped at up to 19.99% (with lower 4.99% or 9.99% options), which can restrict exercises for larger holders. Q32 Bio remains a smaller reporting company with reduced disclosure requirements and emphasizes the high risks typical of early-stage biotechnology development.